Steve Ubl, the leader of PhRMA, plans to step down from the drug industry’s powerful Washington lobbying group, Endpoints News reported, citing sources familiar with the decision.
The exit has brutal timing for PhRMA. Drug pricing reform and pharmaceutical tariffs are both live policy fights, not distant legislative cycles. PhRMA coordinates the drug industry’s unified position on both: pricing legislation that would directly cut into manufacturer revenue, and tariff proposals targeting pharmaceutical imports. Ubl has been the group’s front-line voice in those fights, representing PhRMA’s member companies in Congress and at the White House.
A leadership exit mid-session leaves PhRMA without a front-line voice in Congress. PhRMA represents the drug industry’s largest manufacturers — the companies most exposed to pricing reform and tariff risk. Congressional relationships don’t automatically transfer between executives, and White House access is a function of who is actually in the seat. Ubl has those relationships now; a new leader enters without them, at exactly the moment PhRMA most needs access in Congress and at the White House.
What a successor actually inherits: an active pricing fight and a parallel tariff battle, with a member base that has no appetite for a transition-period holding pattern.
PhRMA hasn’t named a replacement.
Diana Kowalski